Independent Education & Research Resource

Understand GLP-1 & GLP-3 Weight-Loss Science.

Q: How much weight did these peptides produce in clinical trials?

Published clinical trials reported roughly 15-18% body-weight reduction with semaglutide (STEP), up to ~22% with tirzepatide (SURPASS), and ~24%+ with retatrutide at higher doses (NEJM, 2023). These are trial results, not outcomes we promise. Individual results vary, and any treatment decision should be made with your own licensed provider.

Q: Does GLP3 Weight Loss prescribe peptide or provide care?

No. GLP3 Weight Loss is an independent informational resource and research-product catalog. We do not employ clinicians, see patients, prescribe, or dispense peptide. We can refer you to independent, third-party licensed providers who handle any evaluation, prescribing, and care.

Q: What is the Telos research-compound line?

Telos is our catalog of research-grade compounds sold strictly for laboratory and in-vitro research use only. These products are not for human or veterinary use, consumption, or therapeutic purposes, and are not approved by the FDA for treating any condition.

Q: How do I get a prescription if I'm interested in GLP-1 therapy?

Prescription peptides require evaluation by a licensed healthcare provider. We can refer you to independent third-party providers; whether a peptide is appropriate for you is solely between you and that provider. We are not party to that relationship and do not dispense peptide.

Q: What are the common side effects of GLP-1 peptides?

Commonly reported side effects include mild gastrointestinal symptoms such as nausea, which often lessens over time. Serious side effects are possible. This is general information only — discuss risks, contraindications, and monitoring with your own licensed provider before starting any peptide.

Clear, evidence-based education on semaglutide, tirzepatide, and next-generation GLP-3 (retatrutide) research — plus research-use-only compounds. We help you connect with independent licensed providers. We are not a medical provider.

See My Options → Explore the Research

No obligation · Independent licensed providers · All 50 states

Evidence-based

Independent

Research-use-only compounds

Researcher reviewing GLP-1 and GLP-3 weight-loss clinical data

Published Trial Data

~22%

Tirzepatide (SURPASS)

~24%+

Retatrutide (NEJM '23)

~15%

Semaglutide (STEP)

Drug classes explained

NEJM

Peer-reviewed sources

States we publish for

RUO

Research-use-only compounds

Education for All 50 States

Plain-English Drug Science

Peer-Reviewed Sources

Research-Use-Only Compounds

Independent Provider Referrals

Education for All 50 States

Plain-English Drug Science

Peer-Reviewed Sources

Research-Use-Only Compounds

Independent Provider Referrals

How We Help

Learn, Compare, Then Connect

We're an independent resource — not a clinic. We help you understand the science and, if you choose, point you to independent licensed providers who handle any care.

Learn the Science

Read plain-English, citation-backed guides on how GLP-1, GLP-1/GIP, and triple-agonist (GLP-3) compounds work, what trials reported, and how they compare.

Evidence-based

Connect With a Provider

If you want to explore treatment, we can refer you to independent, third-party licensed providers. Any evaluation, prescribing, and care is handled entirely by them — not by us.

Independent providers

Explore Research Compounds

Browse the Telos catalog of research-use-only compounds, sold strictly for laboratory and in-vitro research — not for human use, consumption, or therapeutic purposes.

Research use only

Clinical Evidence

Backed by Peer-Reviewed Science

The figures below are from landmark clinical trials published in leading medical journals. They describe what researchers observed in those studies — not results we offer, promise, or provide.

18-22%

GLP-1 Weight Reduction

STEP & SURPASS Trials

30%+

GLP-3 Weight Reduction

NEJM 2023

↓20%

Major Cardiovascular Events

SELECT Trial, NEJM 2023

14.9%

Semaglutide vs 2.4% Placebo

STEP 1, NEJM 2021

STEP 1 Trial: Semaglutide 2.4mg demonstrated 14.9% mean body weight reduction over 68 weeks versus 2.4% with placebo (NEJM, 2021).

SURPASS 1-4 Trials: Tirzepatide achieved up to 22.5% weight loss at highest dose, with significant HbA1c improvements (NEJM, 2022).

Phase 2 Retatrutide: Triple-agonist achieved 24.2% weight loss at 48 weeks, with the highest dose group exceeding 30% (NEJM, 2023).

SELECT Trial: Semaglutide reduced major adverse cardiovascular events by 20% in patients with overweight/obesity (NEJM, 2023).

Who We Are

An Independent Resource — Not a Clinic

Straight talk about what GLP3 Weight Loss is, and what it isn't.

What we do

Publish independent, citation-backed education on GLP-1 and GLP-3 weight-loss science, and offer a catalog of research-use-only compounds through our Telos line.

What we don't do

We are not a medical practice, pharmacy, or telehealth provider. We do not employ clinicians, see patients, diagnose, prescribe, or dispense peptide. No provider-patient relationship is created by using this site.

How referrals work

If you choose, we can connect you with independent, third-party licensed providers. We may be compensated for referrals. Any care decision is solely between you and that provider.

Retatrutide and other investigational compounds are not approved by the U.S. FDA. All Telos research compounds are sold strictly for laboratory and in-vitro research use only — not for human or veterinary use. Nothing on this page is medical advice; always consult your own licensed healthcare provider.

FAQ

Common Questions

General education about GLP-1 and GLP-3 weight-loss science. This is not medical advice.

What are GLP-1 and GLP-3 peptides?

GLP-1 receptor agonists (such as semaglutide and tirzepatide) are prescription peptides that can reduce appetite, slow gastric emptying, and regulate blood sugar. "GLP-3" is an informal term for next-generation triple-agonist investigational compounds like retatrutide that target GLP-1, GIP, and glucagon receptors. Retatrutide is investigational and not FDA-approved. This is general education, not medical advice.

How much weight did these peptides produce in clinical trials?

Does GLP3 Weight Loss prescribe peptide or provide care?

What is the Telos research-compound line?

How do I get a prescription if I'm interested in GLP-1 therapy?

What are the common side effects of GLP-1 peptides?

Your Next Step

Want to Explore GLP-1 or GLP-3 Therapy?

We can connect you with an independent, licensed provider who can evaluate whether treatment is right for you. Any care is handled entirely by that provider — not by us.

Independent providers

No obligation

We are not a medical provider

See My Options →

Independent provider referral · We may be compensated for referrals